Haralabos P. Kalofonos

TL;DR: Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supported care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy.

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.

TL;DR: It is increasingly recognized that BIPN may be a proteasome inhibitor class effect, producing primarily a small fiber and painful, axonal, sensory distal neuropathy.

TL;DR: In this early development study with a limited number of patients, postoperative MAGE-A3 immunization proved to be feasible with minimal toxicity and is being investigated further in a large phase III study.

TL;DR: The pathogenesis, incidence, risk factors, diagnosis, characteristics and management of OXLIPN are reviewed and the areas of future research are highlighted.